You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Login
Username:

Password:


Related Headlines

Eterna Health and Dr Adeel Khan Pioneer First Regenerative Treatment Using Small Pluripotent Stem Cells (SPSCs)

ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment

Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement

Kyowa Kirin reports new registry data showing overall survival benefit with mogamulizumab in advanced CTCL

Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis

Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD

PureTech highlights Phase 2b data supporting deupirfenidone's safety and efficacy in older IPF patients

Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH

Trellus Health signs contract with leading global CRO and expands clinical trial offerings

GSK reports positive Phase III data for low-carbon version of Ventolin inhaler

Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity

The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director

Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio

Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis

ACG to invest USD200m in US hard-shell capsule manufacturing

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025